The researchers from the Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women’s Hospital and Harvard Medical School point to the example of Mylan’s EpiPen, which still does not have any equivalent competitors, except for Mylan’s own authorized generic, which launched …
